Independent Attestation Review: Food and Drug Administration Fiscal Year 2022 Detailed Accounting Submission and Budget Formulation Compliance Report for National Drug Control Activities and Accompanying Required Assertions
This report provides the results of our review of the Food and Drug Administration Office of National Drug Control Policy (ONDCP) Detailed Accounting Report, which includes the table of Drug Control Obligations, related disclosures, and management's assertions for the fiscal year ended September 30, 2022. We also reviewed the Budget Formulation Compliance Report, which includes budget formulation information for the fiscal year ending September 30, 2024, and the Chief Financial Officer's or accountable senior executive's assertions relating to the budget formulation information.
We performed this review as required by 21 U.S.C. section 1704(d)(1) and as authorized by 21 U.S.C. section 1703(d)(7) and in compliance with the ONDCP Circular National Drug Control Program Agency Compliance Reviews, dated September 9, 2021 (ONDCP Compliance Reviews Circular).
Based on our review, we are not aware of any material modifications that should be made to FDA's Detailed Accounting Report for fiscal year 2022 and FDA's Budget Formulation Compliance Report for fiscal year 2024 and management's assertions for them to be in accordance with the ONDCP Compliance Reviews Circular.
Filed under: Food and Drug Administration
This report may be subject to section 5274 of the National Defense Authorization Act Fiscal Year 2023, 117 Pub. L. 263.